Due to health issues, this site is no longer maintained and will be shut down shortly. |
Genprex Inc is a clinical stage gene therapy company. It develops therapies that carry cancer-fighting genes. Its initial product candidate is Oncoprex.
$0.90 +0.06 (7.14%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.